martes, 6 de octubre de 2015

National Guideline Clearinghouse | Guidelines by Topic: Breast Neoplasms

National Guideline Clearinghouse | Guidelines by Topic

National Guideline Clearinghouse (NGC)



Guidelines by Topic

Breast Neoplasms (71)
21-40 of 71   < Previous Next >
 
21. 
Follow-up care for early-stage breast cancer. 2013 May. NGC:010374
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
22. 
NSGC practice guideline: risk assessment and genetic counseling for hereditary breast and ovarian cancer.2007 Jun (revised 2013 Apr). NGC:009736
National Society of Genetic Counselors - Medical Specialty Society. View all guidelines by the developer(s)
23. 
Adult preventive services (ages 18-49). 2005 Jul (revised 2013 Mar). NGC:009928
Michigan Quality Improvement Consortium - Professional Association. View all guidelines by the developer(s)
24. 
Adult preventive services (ages 50 - 65+). 2005 Jul (revised 2013 Mar). NGC:009929
Michigan Quality Improvement Consortium - Professional Association. View all guidelines by the developer(s)
25. 
26. 
27. 
ACR Appropriateness Criteria® local-regional recurrence (LRR) and salvage surgery—breast cancer. 1996 (revised 2013). NGC:010174
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
28. 
Breast reconstruction following prophylactic or therapeutic mastectomy for breast cancer. 2013 Sep. NGC:010371
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
29. 
Optimal use of taxanes in metastatic breast cancer (MBC). 2013 Sep. NGC:010373
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
30. 
Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. 2012 Oct. NGC:009376
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
31. 
Bevacizumab in combination with capecitabine for the first-line treatment of metastatic breast cancer.2012 Aug. NGC:009311
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
32. 
Sentinel lymph node biopsy and axillary node dissection in early stage breast cancer. 2012 Aug. NGC:009391
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
33. 
Staging investigations for asymptomatic and newly diagnosed breast cancer. 2012 Jul. NGC:009378
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)
34. 
Eribulin for the treatment of locally advanced or metastatic breast cancer. 2012 Apr. NGC:009074
National Institute for Health and Care Excellence (NICE) - National Government Agency [Non-U.S.]. View all guidelines by the developer(s)
35. 
Management of gynecologic issues in women with breast cancer. 2012 Mar. NGC:008958
American College of Obstetricians and Gynecologists - Medical Specialty Society. View all guidelines by thedeveloper(s)
36. 
ACR Appropriateness Criteria® breast cancer screening. 2012. NGC:009213
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
37. 
ACR Appropriateness Criteria® nonpalpable mammographic findings (excluding calcifications). 1996 (revised 2012). NGC:009657
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
38. 
ACR Appropriateness Criteria® palpable breast masses. 1996 Sep (revised 2012). NGC:009658
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
39. 
ACR Appropriateness Criteria® postmastectomy radiotherapy. 1996 (revised 2012). NGC:009229
American College of Radiology - Medical Specialty Society. View all guidelines by the developer(s)
40. 
Bone health in patients with breast cancer. 2012 Nov. NGC:010372
CancerControl Alberta - State/Local Government Agency [Non-U.S.]. View all guidelines by the developer(s)

No hay comentarios:

Publicar un comentario